financetom
Business
financetom
/
Business
/
--L3Harris Technologies CEO Kubasik Expects to Exceed 2024 Cost Savings Target of $400 Million
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
--L3Harris Technologies CEO Kubasik Expects to Exceed 2024 Cost Savings Target of $400 Million
Nov 3, 2024 11:10 AM

04:46 PM EDT, 10/24/2024 (MT Newswires) --

Price: 254.49, Change: +10.32, Percent Change: +4.23

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Brazil's Nubank partners with convenience store Oxxo to expand in Mexico
Brazil's Nubank partners with convenience store Oxxo to expand in Mexico
Jan 13, 2025
SAO PAULO, Jan 13 (Reuters) - Brazilian digital lender Nubank has signed an agreement with Mexican convenience store chain Oxxo, run by FEMSA, to expand its cash deposit and withdrawal network in the North American country, the firms announced on Monday. WHY IT'S IMPORTANT Warren Buffett-backed Nubank, one of the Latin America's largest firms by market value, has been aiming...
What's Going On With Vera Therapeutics Stock?
What's Going On With Vera Therapeutics Stock?
Jan 13, 2025
Vera Therapeutics Inc ( VERA ) shares are trading lower by 7.3% to $34.31 Monday afternoon. The company announced an exclusive license agreement with Stanford University for VT-109. What To Know: Vera Therapeutics ( VERA ) has secured an exclusive license from Stanford University for VT-109, a next-generation fusion protein targeting BAFF and APRIL. VT-109 offers broad therapeutic potential for...
National Bank Lowers CN Rail Target to $178
National Bank Lowers CN Rail Target to $178
Jan 13, 2025
02:22 PM EST, 01/13/2025 (MT Newswires) -- National Bank has trimmed its target on CN Rail to $178, from $181, but kept its Outperform rating ahead of fourth-quarter results. Investor patience with the stock is likely wearing thin following a forgettable 2024 performance from CN and tariff risk is likely to remain an overhang in the near term, writes analyst...
Apellis Shares Rise After Reporting Preliminary Q4, Full-Year Product Sales Results
Apellis Shares Rise After Reporting Preliminary Q4, Full-Year Product Sales Results
Jan 13, 2025
02:23 PM EST, 01/13/2025 (MT Newswires) -- Apellis Pharmaceuticals ( APLS ) shares were up 4% in recent trading Monday after the company reported preliminary full-year 2024 US net product revenue of $709 million for Syfovre and Empaveli. Analysts polled by FactSet expected 2024 combined sales of $710 million for the two products. The company said the preliminary figure includes...
Copyright 2023-2026 - www.financetom.com All Rights Reserved